ReviewFrontiers in pharmacology2020
Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 111 citations in OpenAlex.
- Development of a gut microbiota model for the analysis of bacterial modifications of xenobiotics.Applied microbiology and biotechnology · 2026Article
- Immunomodulatory Role of Milk on Gut Microbiota: Implications for Enhancing Oral Vaccine Efficacy.Probiotics and antimicrobial proteins · 2026Review
- Microbiome-Driven Mechanisms in Breast Cancer: Emerging Evidence From Gut Microbial Signatures to Therapeutic Response.BioMed research international · 2026Review
- Associations between rivaroxaban dose, gut microbiota, and coagulation parameters in a rat model.Thrombosis journal · 2025Article
- Application ofFoods (Basel, Switzerland) · 2025Review
- Gut as a Target of Ochratoxin A: Toxicological Insights and the Role of Microbiota.International journal of molecular sciences · 2025Review
- Mechanisms and implications of the gut microbial modulation of intestinal metabolic processes.npj metabolic health and disease · 2025Review
- Live Biotherapeutic Products for Metabolic Diseases: Development Strategies, Challenges, and Future Directions.Journal of microbiology and biotechnology · 2025Review
- Impact of Ex Vivo Bisphenol A Exposure on Gut Microbiota Dysbiosis and Its Association with Childhood Obesity.Journal of xenobiotics · 2025Article
- Hydroclimatic extremes threaten groundwater quality and stability.Nature communications · 2025Article
- Machine Learning in Early Prediction of Metabolism of Drugs.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Synergistic therapy of Chinese herbal medicine and gut microbiota modulation for post-stroke cognitive recovery: focus on microbial metabolite and immunoinflammation.Frontiers in microbiology · 2025Review
- Molecular Mimicry Between Gut Microbiome and Rheumatoid Arthritis: Current Concepts.Medical sciences (Basel, Switzerland) · 2024Review
- Guardians of the Gut: Harnessing the Power of Probiotic Microbiota and Their Exopolysaccharides to Mitigate Heavy Metal Toxicity in Human for Better Health.Probiotics and antimicrobial proteins · 2024Review
- Mitigating Dietary Bisphenol Exposure Through the Gut Microbiota: The Role of Next-Generation Probiotics in Bacterial Detoxification.Nutrients · 2024Review
- Article
- Exposure to environmental pollutants selects for xenobiotic-degrading functions in the human gut microbiome.Nature communications · 2024Observational
- Bisphenol A exposure affects specific gut taxa and drives microbiota dynamics in childhood obesity.mSystems · 2024Article
- Who inhabits the built environment? A microbiological point of view on the principal bacteria colonizing our urban areas.Frontiers in microbiology · 2024Review
- The potential of including the microbiome as biomarker in population-based health studies: methods and benefits.Frontiers in public health · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The harmful impact of xenobiotics on the environment and human health is being more widely recognized; yet, inter- and intraindividual genetic variations among humans modulate the extent of harm, mostly through modulating the outcome of xenobiotic metabolism and detoxification. As the Human Genome Project revealed that host genetic, epigenetic, and regulatory variations could not sufficiently explain the complexity of interindividual variability in xenobiotics metabolism, its sequel, the Human Microbiome Project, is investigating how this variability may be influenced by human-associated microbial communities. Xenobiotic-microbiome relationships are mutual and dynamic. Not only does the human microbiome have a direct metabolizing potential on xenobiotics, but it can also influence the expression of the host metabolizing genes and the activity of host enzymes. On the other hand, xenobiotics may alter the microbiome composition, leading to a state of dysbiosis, which is linked to multiple diseases and adverse health outcomes, including increased toxicity of some xenobiotics. Toxicomicrobiomics studies these mutual influences between the ever-changing microbiome cloud and xenobiotics of various origins, with emphasis on their fate and toxicity, as well the various classes of microbial xenobiotic-modifying enzymes. This review article discusses classic and recent findings in toxicomicrobiomics, with examples of interactions between gut, skin, urogenital, and oral microbiomes with pharmaceutical, food-derived, and environmental xenobiotics. The current state and future prospects of toxicomicrobiomic research are discussed, and the tools and strategies for performing such studies are thoroughly and critically compared.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.